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The mechanisms that regulate the induction of term or preterm delivery (PTD) are not fully understood. Infection is known to play a role
in the induction of pro-inflammatory cascades in uteroplacental tissues associated with preterm pathological parturition. Similar but not
identical cascades are evident in term labour. In the current study, we used a mouse model to evaluate the role of prokineticins in term
and preterm parturition. Prokineticins are multi-functioning secreted proteins that signal through G-protein-coupled receptors to induce
gene expression, including genes important in inflammatory responses. Expression of prokineticins (Prok1 and Prok2) was quantified in
murine uteroplacental tissues by QPCR in the days preceding labour (days 16–19). Prok1 mRNA expression increased significantly on
D18 in fetal membranes (compared with D16) but not in uterus or placenta. Intrauterine injection of PROK1 on D17 induced fetal
membrane mRNA expression of the pro-inflammatory mediators Il6, Il1b, Tnf, Cxcl2 and Cxcl5, which are not normally up-regulated
until D19 of pregnancy. However, intrauterine injection of PROK1 did not result in PTD. As expected, injection of lipopolysaccharide
(LPS) induced PTD, but this was not associated with changes in expression of Prok1 or its receptor (Prokr1) in fetal membranes.
These results suggest that although Prok1 exhibits dynamic mRNA regulation in fetal membranes preceding labour and induces a pro-
inflammatory response when injected into the uterus on D17, it is insufficient to induce PTD. Additionally, prokineticin up-regulation
appears not to be part of the LPS-induced inflammatory response in mouse fetal membranes.
Reproduction (2013) 146 581–591Introduction
The factors that trigger the onset of parturition at term in
humans (w39 weeks) are not yet fully understood,
although inflammation in uteroplacental tissues and
increased priming of leukocyte activation in maternal
peripheral blood are well documented (Peltier 2003,
Haddad et al. 2006, Bollapragada et al. 2009, Challis et al.
2009, Yuan et al. 2009). The cervix and uteroplacental
tissues (myometrium, placenta and fetal membranes)
demonstrate elevated leukocyte numbers and cytokine
production during parturition at term (Denison et al. 1998,
Thomson et al. 1999,Younget al. 2002, Osman et al. 2003,
2006). Increased interleukin 1B (IL1B), IL6, IL8 and
tumour necrosis factor (TNF) production by recruited and
resident immune cells leads to induction of matrix
metalloproteinases (MMPs) that facilitate cervical ripening
and membrane rupture (Watari et al. 1999, Allport et al.
2001, Kelly 2002, Xu et al. 2002, Young et al. 2002,
Timmons et al. 2010). In myometrium, IL1B, IL6 and
TNF contribute to the onset and synchronisation of
contractions by inducing calcium release and expressionq 2013 The authors
ISSN 1470–1626 (paper) 1741–7899 (online)
DOI: 10.1530/REP-13-0295
Online version via www.reproduction-online.orgof cyclo-oxygenase (COX) enzymes, prostaglandin
synthesis and expression of prostaglandin and oxytocin
receptors (Friebe-Hoffmann et al. 2001, Tribe et al. 2003,
Zaragoza et al. 2006, Fitzgibbon et al. 2009).
Preterm delivery (PTD) in humans is considered to
occur before 37 weeks of gestation and is the largest cause
of neonatal mortality and morbidity in the developed
world (Norman et al. 2009, Beck et al. 2010). Although the
aetiology is not fully understood, there are several factors
that are associated with increased risk (Goldenberg et al.
2008) including inflammation/infection in the reproduc-
tive tract (Goldenberg et al. 2000). Inflammation in
uteroplacental tissues can occur in response to bacterial
invasion of the reproductive tract as part of the innate
immune response (Romero et al. 2006) but also occurs in
its absence (Tornblom et al. 2005). The likely sequence
of events is that immune cells and tissues expressing
toll-like receptors (TLRs) recognise pathogen-associated
molecular patterns including lipopolysaccharide (LPS), a
component of the cell wall of Gram-negative bacteria. LPS
binding to TLR4 (along with CD14 and MD-2) leads to
activation of the transcription factor NFKB, a majorThis work is licensed under a Creative Commons
Attribution 3.0 Unported License.
Table 1 Treatments and sample size for mouse model of PTL.
Treatment group Number of dams
Natural delivery 5
Saline 15
LPS 10
PROK1 16
582 T R M Lannagan and othersregulator of pro-inflammatory mediators (Akira et al.
2006, Doyle & O’Neill 2006), resulting in the premature
expression of cytokines and chemokines in gestational
tissues. This process culminates in early onset of cervical
ripening, uterine contractions and PTD. In addition,
premature inflammation in uteroplacental tissues is
implicated in fetal inflammatory injury, an adverse
neonatal outcome (Goepfert et al. 2004). Current
therapies for preterm labour attempt to delay the onset
of parturition; however, additionally targeting the
inflammatory response could not only delay parturition
but also reduce fetal inflammatory injury.
Fetal membranes in humans comprise amnion and
chorion and an extracellular matrix. At term parturition
the fetal membranes overlying the cervix rupture;
evidence suggests that this is due to reduced collagen
levels and increased apoptosis. However, a role for fetal
membrane activation in PTD has also been described as
clinical and histological chorioamnionitis (inflammation
of the amnion and chorion) can lead to preterm premature
rupture of membranes (pPROM) (reviewed by Menon &
Fortunato (2007) and Gomez-Lopez et al. (2010)).
PTD can be artificially induced by treating pregnant
mice with LPS (via the i.p., intrauterine, intra-amniotic or
vaginal routes), allowing the effect of preterm labour (and
potential therapeutic targets) on neonatal morbidity and
mortality to be investigated (Elovitz et al. 2003, Pirianov
et al. 2009, Burd et al. 2010, Gonzalez et al. 2011).
In silico data (Catalano et al. 2010) suggest that
another target of NFKB transcriptional regulation in
response to LPS could be the multi-functional secreted
proteins prokineticin 1 (PROK1) and PROK2 and their
G-protein-coupled receptors (GPCRs: PROKR1 and
PROKR2). Prokineticins can regulate a wide variety of
biological processes including angiogenesis, haemato-
poiesis, nociception, circadian rhythms, smooth muscle
contractility and inflammatory responses (LeCouter et al.
2001, Li et al. 2001, Negri et al. 2002, Cheng et al. 2005,
Dorsch et al. 2005, Maldonado-Perez et al. 2007,
Monnier & Samson 2008, Ngan & Tam 2008). In relation
to pregnancy and parturition, it is also known that
prokineticins play a role in establishing early pregnancy
(Evans et al. 2008, 2009, Waddell et al. 2011) and in
pathological conditions such as pre-eclamspia and
ectopic pregnancy (Hoffmann et al. 2006, 2009, Shaw
et al. 2010). In addition, we have recently demonstrated
that prokineticins are up-regulated at term in uteropla-
cental tissues and that ex vivo treatment with PROK1
induces a cascade of pro-inflammatory pathways in
human placenta and myometrial tissue collected from
pregnant women at term (Denison et al. 2008, Gorowiec
et al. 2011). These data taken together demonstrate the
potential role for prokineticins in regulating inflam-
matory pathways associated with term parturition and
therefore their possible involvement in preterm labour.
This study was designed to characterise the expression
of prokineticins in mouse uteroplacental tissues in theReproduction (2013) 146 581–591days preceding labour and to investigate the role of
prokineticins in term and preterm parturition using a
mouse model of infection-induced PTD .Materials and methods
Mouse model of PTL
CD1 outbred, timed pregnant mice were purchased from Charles
River (Margate, Kent, UK) and allowed at least 6 days of
acclimatisation prior to surgery. Pregnant females or virgin
female and proven males were purchased pregnant and timed-
mated within the University of Edinburgh facility. Surgery was
performed on day 17 of pregnancy (D17; day plug found is D1 of
pregnancy). Dams were anaesthetised with isoflurane and
both uterine horns exposed following laparotomy. The number
of viable fetuses in each horn was recorded and the horn
containing the most fetuses was selected for intrauterine
injection. Using a 33-gauge Hamilton syringe, pregnant mice
were injected between the two most anterior fetuses with either a
25 ml volume of sterile saline (Sigma); recombinant mouse
PROK1 (R&D Systems, Abingdon, Oxford, UK) diluted to
350 nM in saline (dose based on highest concentration shown
to induce cell proliferation in bovine endothelial cells in vitro,
ED50 of 4 mg/ml, determined by R&D Systems, and nearly ten
times the dose that induces cytokine expression in human
gestational tissues (Maldonado-Perez et al. 2009); or 20 mg LPS
(Sigma) in saline (see Table 1 for summary of treatments and
sample sizes). The body wall was closed using a continuous
suture and the skin closed using single stitches. Dams received
Vetergesic analgesia (Reckitt Benckiser Healthcare, Kingston-
upon-Thames, UK) and were allowed to recover in a warm
environment prior to single housing and monitoring for delivery
(infra-red cameras and digital video recorder purchased from RF
Concepts (Dundonald, UK)). The time to delivery was the number
of hours recorded from injection to delivery of the first pup. To
record the time taken for natural delivery (in the absence of
surgery), the average time of saline injection was calculated and
used as a theoretical time point from which to calculate the time
to delivery. Pup survival wascalculated as the number of live pups
found in the cage (or dam) at the time of culling as a proportion of
the total number of viable fetuses recorded at injection. Animals
were housed under standard conditions and had access to food
and water ad libitum. All animal care and experimental protocols
were approved by the animal ethics committee of the University
of Edinburgh and the Home Office of the UK government.Amniotic fluid collection, tissue harvesting and
processing
Tissue was collected from timed-mated CD1 mice on D16–19
of pregnancy (parturition occurred on D20). Dams were culledwww.reproduction-online.org
Table 2 Treatments and sample size for gestational tissue and in vivo
experiments.
Tissue sample
Stage of gestation/
treatment
Number of dams/
samples collected
per dam
Fetal membranes D16 gestation 10/1
Fetal membranes D17 gestation 9/1
Fetal membranes D18 gestation 10/1
Fetal membranes D19 gestation 10/1
Fetal membranes D17 6 h saline 4/3
Fetal membranes D17 6 h LPS 4/3
Fetal membranes D17 6 h PROK1 6/3
Amniotic fluid D17 6 h saline 4/4–6
Amniotic fluid D17 6 h LPS 4/4–6
Amniotic fluid D17 6 h PROK1 R5/4–6
Prokineticin 1 and mouse fetal membranes 583by cervical dislocation and uterus, placenta and fetal
membranes separated, and collected into RNAlater (Ambion
(Life Technologies Ltd, Paisley, UK)) for RNA extraction or fixed
in 4% neutral buffered formalin and wax embedded for
immunohistochemistry (see Table 2 for summary of treatments
and sample sizes). Similar collection protocols were applied
2 or 6 h after intrauterine injection of saline, LPS or PROK1 (as
described earlier for the mouse model of PTD). In addition, for
the 6-h time point, amniotic fluid was collected and pooled
from four to six fetuses (i.e. one sample per dam).Table 3 Sequences of mouse primers and probes used in QPCR.
Gene Primer/probe sequence (5 0–3 0) Control tissue
Prok1 F: GAAGCCACAAGATCCCCTTCT D19 fetal membrane
R: TGCCGTCCGGGAACCT
Probe (FAM/TAM): AAACGCCAA-
CACCATACCTGTCCCTG
Prokr1 F: TGGCCCGCTACAAAAAGCT Adult liver
R: CCACGAGGAAGTCT-
GAAATGG
Probe (FAM/TAM): CGCAACCT-
CACCAACCTGCTTATCG
Il6 F: CCACGGCCTTCCCTACTTC D19 fetal membrane
R: TGCACAACTCTTTTCT-
CATTCCA
Probe (FAM/TAM): TCACAGAG-
GATACCACTCCCAACA-
GACCTG
Ptgs2 F: GCTTCGGGAGCACAACAG D19 fetal membraneTaqMan quantitative RT-PCR
Total RNA was extracted from tissue using QIAzol lysis
reagent, phase lock tubes and the RNeasy mini kit with
on-column DNase digestion from Qiagen, according to the
manufacturer’s guidelines. RNA concentration was quantified
using a Nanodrop (Thermo Scientific, Hemel Hempstead, UK)
and diluted to 100 ng/ml in RNase-free water (Invitrogen)
before RT using the Superscript VILO cDNA synthesis kit
(Invitrogen). PCRs were carried out using Applied Biosystems
7500 and 7900 Fast instruments. Primer and FAM (6-carboxy-
fluorescein)-labelled probe sequences were designed to span
an intron (where possible) and purchased from Sigma
(Table 3) or TaqMan Gene Expression Assays were purchased
from Applied Biosystems (Table 4). Expression was normalised
for RNA loading using actin (Actb) primers designed to span
an intron and JOE-labelled probe (Sigma; Table 3). Relative
expression in each sample was calculated against the level of
expression detected in a tissue known to express the target
gene (Tables 3 and 4). To compare the changes in pro-
inflammatory mediator expression in response to intrauterine
injection of LPS or PROK1 with those occurring endogenously
at term, fold changes were calculated by dividing the
mean relative expression in the treated group by the mean
relative expression in the saline group, and by dividing mean
relative expression on D19 with that on D17 (the day on
which surgery was carried out).R: TGGTTTGGAATAGTTGCTC
Probe (FAM/TAM): TGTGCGACA-
TACTCAAGCA
Actb F: GCTTCTTTGCAGCTCCTTCGT NA
R: GCGCAGCGATATCGTCATC
Probe (JOE/TAM): CACCCGC-
CACCAGTTCGCCATImmunohistochemistry
Paraffin-embedded tissue was processed for immunohisto-
chemistry as described in Catalano et al. (2011) with either
rabbit anti-human PROK1 at 1:750 dilution (Phoenixwww.reproduction-online.orgPharmaceuticals (Belmont, CA, USA), H-023-59) or rabbit
anti-human PROKR1 at 1:750 dilution (Caltag Medsystems,
Buckingham, UK; LS-A6684). Negative controls were incu-
bated without primary antibody. Sections were imaged using a
Provis AX70 microscope (Olympus, Southend-on-Sea, UK) and
photographed using an AxioCam HRc with AxioVision Release
4.8 (Carl Zeiss Ltd., Berlin, Germany).Cytokine assays
Amniotic fluid collected from saline-, LPS- or PROK1-treated
dams was quantified by ELISA Quantikine Kits (R&D Systems)
for mouse IL1B (MLB00B), TNF (MTA00) and CXCL2 (MM200)
as per kit instructions.Statistical analysis
Data that passed the normality test (Kolmogorov–Smirnov)
were subjected to statistical analysis using a one-way ANOVA
with Tukey’s multiple comparison post-test or a two-tailed
unpaired t-test. Nonparametric data were subjected to Kruskal–
Wallis test with Dunn’s post-test or a two-tailed Mann–Whitney
U test. Percentages were arcsine transformed prior to analysis
as they cannot be normally distributed (no values !0 and
nothingO100). Where more than one fetus was collected per
dam the data was averaged per dam. All analysis was carried
out using GraphPad Prism and GraphPad Software, Inc. (La
Jolla, CA, USA). Significance was defined as P!0.05.Results
Expression of prokineticins in murine uteroplacental
tissues across the days preceding parturition
Expression of Prok1 and Prokr1 mRNA was examined
daily in fetal membranes from D16 to 19 of pregnancyReproduction (2013) 146 581–591
Table 4 Mouse ABI TaqMan gene expression assays used in QPCR.
Gene ABI assay code Control tissue
Prok2 Mm01182450_g1 D16 uterus
Prokr2 Mm00769571_m1 D16 uterus
Cxcl2 Mm00436450_m1 D19 fetal membrane
Cxcl5 Mm00436451_g1 D19 fetal membrane
Il1b Mm01336189_m1 D19 uterus
Tnf Mm00443258_m1 D19 uterus
Ptgs1 Mm00477214_m1 D19 uterus
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584 T R M Lannagan and others(animals delivered on D20 of pregnancy; one fetal
membrane from a minimum of nine to ten dams). On
D18, expression of Prok1 mRNA was significantly
greater when compared with expression on D16 and
17 (P!0.001; Fig. 1A) and Prokr1 expression was
significantly lower on D18 and 19 when compared
with D16 (P!0.01 and P!0.05 respectively; Fig. 1B).
Protein expression of PROK1 and PROKR1 in fetal
membranes was investigated by immunohistochemistry
between D16 and 19. No change in localisation was
observed during this period, although PROK1 expression
was stronger in D19 fetal membranes than those in D16
(Fig. 2, D17–18, not shown). PROK1 and PROKR1 were
localised in the amnion epithelium (Fig. 2A, C, F and H).
In the yolk sac (considered to be equivalent to the
human chorion), PROK1 and PROKR1 were localised
to the epithelium, mesoderm and endothelial cells
(Fig. 2B, D, G and H).
Expression analysis of Prok1 in the uterus and placenta
revealed no significant change across D16–19 (one
tissue sample from a minimum of four to five dams;
Supplementary Figure 1A and C, see section on
supplementary data given at the end of this article).
Prokr1 expression decreased towards the end of
gestation in the uterus (D19 vs D16 and 17, P!0.05;
Supplementary Figure 1B) and placenta (D19 vs 17,
P!0.05; Supplementary Figure 1D).
Expression of Prok2 and Prokr2 was also examined in
the same uteroplacental tissue samples from D16 to 19.
Fetal membrane Prok2 expression increased by a small
but significant amount on D18 when compared with
expression on D16 (P!0.05; Supplementary Figure 2A,
see section on supplementary data given at the end of
this article). No changes were detected for Prokr2 in
the fetal membranes (Supplementary Figure 2B). No
significant changes were detected for either Prok2 or
Prokr2 in the uterus and placenta (Supplementary
Figure 2C, D, E and F).Day of pregnancy
Figure 1 Prok1 mRNA expression peaks on D18 of pregnancy in murine
fetal membranes. QPCR expression analysis of Prok1 (A) and Prokr1
(B) in murine fetal membranes reveals dynamic regulation preceding
labour (D16–19). The graphs show individual values for each sample
(one membrane analysed per mouse), mean expression levels are in
arbitrary units normalised to Actb mRNA, error bars representGS.E.M.
(ANOVA). D16 (nZ10), D17 (nZ9), D18 (nZ10) and D19 (nZ10).
Note: logarithmic scale.Intrauterine injection of LPS or PROK1 enhances
expression of pro-inflammatory mediators in fetal
membranes
LPS treatment is well documented to induce pro-
inflammatory responses in many tissues. In this study,
we investigated the pro-inflammatory response of fetal
membranes to LPS and PROK1 in vivo using a model ofReproduction (2013) 146 581–591infection-induced PTD. For this, fetal membranes were
collected 6 h after intrauterine injection with saline
(control; average of three fetal membranes collected
from each of four dams), LPS (average of three fetal
membranes collected from each of four dams) or PROK1
(average of three fetal membranes collected from each of
six dams). Compared with the saline treatment, relative
expression of prostaglandin synthase 2 (Ptgs2, also
referred to as COX2), Il6, Il1b, Tnf, chemokine (CXC
motif) ligand 2 (Cxcl2) and Cxcl5 mRNAs were found to
be significantly increased in response to LPS treatment
(Fig. 3). By contrast, expression of Ptgs1 (a gene chosen
as a negative control) did not change in response to
treatment with LPS. Similarly, Prok1 and Prokr1
expression levels were not regulated by LPS treatmentwww.reproduction-online.org
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Figure 2 PROK1 and PROKR1 are expressed at the protein level by murine fetal membranes preceding labour. Immunohistochemical localisation of
PROK1 (A, B, C and D) and PROKR1 (F, G, H and I) in D16 (A, B, F and G) and D19 (C, D, H and I) murine fetal membranes revealed that PROK1 is
localised in the epithelium of amnion and yolk sac (see arrows in (A, B, C and D)) and in mesenchyme (asterisk) and endothelium (arrowhead) of the
yolk sac (B). PROKR1 is expressed in the epithelium of amnion and yolk sac (see arrows in (F, G, H and I)) and in mesenchyme (asterisk in (G)) and
endothelium of yolk sac (arrowhead in (I)). (E and J) Negative controls for PROK1 and PROKR1 respectively.
Prokineticin 1 and mouse fetal membranes 585at the 6-h time point (Fig. 3) or earlier at 2 h (data
not shown). Intrauterine administration of PROK1
significantly increased expression of Il6, Il1b, Tnf,
Cxcl2 and Cxcl5 but not Ptgs2 or Ptgs1 by 6 h after
treatment (Fig. 4).
We subsequently investigated the temporal expression
of Ptgs2, Il6, Il1b, Tnf, Cxcl2 and Cxcl5 between D16
and 19 of pregnancy and all were shown to significantly
increase on D19 in fetal membranes (Supplementary
Figure 3, see section on supplementary data given at the100
P < 0.05
10
1
Saline
Ptgs2A
m
R
N
A
re
la
tiv
e 
ex
pr
es
sio
n 
(lo
g)
LPS
0.1
1000
P < 0.05
150
100
50
Saline
Il6B
m
R
N
A
re
la
tiv
e 
ex
pr
es
sio
n 
(lo
g)
LPS
0
1000
150
100
50
Sali
C
m
R
N
A
re
la
tiv
e 
ex
pr
es
sio
n 
(lo
g)
0
10
P < 0.05
1
0.1
0.01
Saline
Cxcl5F
m
R
N
A
re
la
tiv
e 
ex
pr
es
sio
n 
(lo
g)
LPS
0.001
1
NS
0.1
Saline
Prok1G
m
R
N
A
re
la
tiv
e 
ex
pr
es
sio
n 
(lo
g)
LPS
0.01
10
1
0.1
Sali
H
m
R
N
A
re
la
tiv
e 
ex
pr
es
sio
n 
(lo
g)
Figure 3 Intrauterine injection of LPS induces a pro-inflammatory response i
mRNA expression analysis of (A) Ptgs2, (B) Il6, (C) Il1b, (D) Tnf, (E) Cxcl2, (F)
after intrauterine injection of LPS reveals up-regulation of pro-inflammator
The graphs show mean values for each dam (three membranes analysed pe
Actb mRNA, error bars representGS.E.M. (t-test). Saline (nZ4 dams) and LP
www.reproduction-online.orgend of this article). Using relative expression values, we
compared the endogenous changes occurring in fetal
membranes at the onset of parturition with those
occurring in response to PROK1 or LPS (Table 5).
Endogenous levels on D19 were compared with levels
on D17. Apart from Tnf, overall expression of pro-
inflammatory genes in response to intrauterine injection
of 350 nM PROK1 was comparable (less than twofold
greater) or lower than seen endogenously on D19 of
pregnancy. Intrauterine injection of 20 mg LPS resulted inP < 0.05
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Figure 4 Intrauterine injection of PROK1 induces a pro-inflammatory
response in murine fetal membranes. QPCR expression analysis of
pro-inflammatory mediators (B) Il6, (C) Il1b, (D) Tnf, (E) Cxcl2 and
(F) Cxcl5 in murine membranes 6 h after intrauterine injection of
PROK1 reveals their up-regulation but not of (A) Ptgs2 or (G) Ptgs1
(negative control). Each data point represents the mean response for
each dam (three membranes per dam) and the graphs show the mean
response per treatment group. Mean expression levels are in arbitrary
units normalised to Actb mRNA, error bars representGS.E.M. (t-test).
Saline (nZ4 dams) and PROK1 (nZ6 dams). NS, non-significant.
Note: logarithmic scale.
Table 5 Fold changes in relative expression of pro-inflammatory
mediators in mouse fetal membranes between D17 (nZ9) and D19
(nZ10) of pregnancy, between 6-h saline (nZ4) and PROK1 (nZ6)
intrauterine injection, and between 6-h saline and LPS (nZ4)
intrauterine injection.
Gene
Endogenous
D17 vs 19
Saline vs
PROK1 Saline vs LPS
Ptgs2 1.73 2.61 13.74
Il6 12.04 18.68 62.80
Il1b 11.08 17.74 81.43
Tnf 2.94 12.54 12.76
Cxcl2 90.19 37.52 290.67
Cxcl5 440.16 22.45 62.26
586 T R M Lannagan and othersa greater fold increase in expression of pro-inflammatory
genes compared with PROK1 and those measured
endogenously on D19 (apart from Cxcl5). Interestingly,
it was the chemokines Cxcl2 and Cxcl5 that showed the
most striking differential expression in response to either
term parturition or LPS treatment.Reproduction (2013) 146 581–591Intrauterine injection of LPS but not PROK1
regulates production of pro-inflammatory mediators
in amniotic fluid
To compare the pro-inflammatory stimuli (LPS and
PROK1), levels of secreted IL1B, TNF and CXCL2 were
measured by ELISA in amniotic fluid collected 6 h after
intrauterine injection (amniotic fluid was pooled from
the amniotic sacs of four to six fetuses). Unexpectedly, a
different pattern of results was obtained for each protein.
IL1B was not regulated by either treatment, although
PROK1 did demonstrate a trend for higher levels than
LPS (saline, 46.60G7.72 pg/ml; PROK1, 69.12G
15.85 pg/ml and LPS, 41.03G9.96 pg/ml; Fig. 5A). All
samples from saline-treated animals contained undetect-
able levels of TNF, as did half of the PROK1-treated
samples (saline, 0G0 pg/ml and PROK1, 1.30G0.60 pg/
ml). By contrast, all LPS-treated samples contained
detectable TNF (47.95G18.67 pg/ml) and the mean
was significantly higher than the saline control (P!0.05;
Fig. 5B). Measurement of CXCL2 revealed a similar
pattern to TNF, with PROK1-treated samples demonstrat-
ing a trend for greater concentration than saline-treated
samples (although not significant; saline, 50.57G
7.60 pg/ml and PROK1, 101.00G21.33 pg/ml) while
the LPS-treated samples contained a significantly higher
concentration (1121.08G13.63 pg/ml; P!0.01).Intrauterine injection of PROK1 does not induce PTD
In order to investigate the effect of PROK1 on PTD, three
groups of mice received intrauterine injection of saline,
LPS or PROK1 on D17 of pregnancy (Fig. 6A). The time
to delivery for mice treated with saline was 50.50G
4.79 h (nZ15). The time to delivery in dams treated with
PROK1 (39.19G4.87 h; nZ16) was not significantly
different from the time to delivery in dams treated with
saline. However, treatment with LPS significantly
reduced the time to delivery (17.90G2.65 h; nZ10)
compared with treatment with saline (P!0.001) or
PROK1 (P!0.05). To assess whether or not surgery itself
affected time to delivery, the time taken for five dams towww.reproduction-online.org
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Figure 5 Intrauterine injection of LPS but not PROK1 increases the
levels of secreted cytokines in murine amniotic fluid. Protein
quantification of IL1B, TNF and CXCL2 by ELISA in amniotic fluid 6 h
after intrauterine injection of LPS (A, C and E) or PROK1 (B, D and F)
reveals significant up-regulation of TNF and CXCL2 in response to LPS
but not PROK1 and no increase in IL1B to either treatment. Each data
point represents the mean response for each dam (amniotic fluid from
four to six sacs per dam) and the graphs show the mean response
per treatment group. Mean expression levels (pg/ml), error bars
representGS.E.M. (t-test). NS, non-significant.
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Prokineticin 1 and mouse fetal membranes 587naturally deliver was recorded (54.24G4.00 h; not
significantly different from the saline-treated group).
Another measure of the effect of infection-induced
PTD is to record pup survival (Fig. 6B). The average
percentage of pups surviving per dam (calculated from
the number of live pups in the cage or in the dam at time
of culling) was significantly reduced in mice treated with
LPS (15.33G6.08%) compared with treatment with
saline or PROK1 (88.57G3.22% and 82.87G4.46%
respectively; P!0.001).Saline
Pe
rc
en in
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LPS PROK1
20
0
Figure 6 Intrauterine injection of PROK1 does not induce PTD. Time
to delivery of first pup (A) and percentage pup survival per dam
(B) following intrauterine injection of saline, LPS (20 mg) or PROK1
(350 nM) were compared. The number of hours to natural delivery
(nonsurgical) was not significantly different from saline-treated dams
but LPS treatment significantly reduced the time to delivery. Error bars
representGS.E.M. (ANOVA). Natural delivery (nZ5 dams), saline
(nZ15 dams), LPS (nZ10 dams) and PROK1 (nZ16 dams). NS,
non-significant.Discussion
In humans, term parturition and PTD are considered pro-
inflammatory events (Bowen et al. 2002, Challis et al.
2009, Catalano et al. 2010, Golightly et al. 2011).
PROK1 mRNA expression is increased in human
placenta and myometrium at term, and ex vivo treatment
of these tissues with PROK1 induces a pro-inflammatory
response (Denison et al. 2008, Gorowiec et al. 2011).
Ex vivo treatment of term human myometrium with LPSwww.reproduction-online.orgup-regulates expression of PROK1 and PROKR1
(Gorowiec et al. 2011). In addition, PROK1 is a potent
stimulator of smooth muscle contractions in the gut
(Li et al. 2001, Wade et al. 2010). We hypothesised
that PROK1 could be a potential mediator of pro-
inflammatory pathways in human labour at term and
may directly induce smooth muscle (myometrial)
contractions. Thus, PROK1 induction may be part of
the infection-induced pro-inflammatory response that
contributes to PTD and antagonism of PROK1 could be a
therapeutic target in the treatment of PTD.
We used the mouse as a model to investigate the role
of prokineticins in parturition and PTD. Previously in the
mouse, analysis of prokineticin expression in uteropla-
cental tissues has been restricted to the placenta
(Hoffmann et al. 2007). Protein and mRNA expressionsReproduction (2013) 146 581–591
588 T R M Lannagan and othersof Prok1 and Prokr1 were examined on 9.5, 10.5, 14.5
and 17.5 days post-coitus (dpc) and expression of
both was significantly down-regulated after 10.5dpc,
indicating a role in early placentation (Hoffmann et al.
2007). Therefore, we carried out the first daily exami-
nation of prokineticin expression in uteroplacental
tissues preceding parturition in the mouse. Our data
demonstrate that there is a dramatic up-regulation of
Prok1 mRNA in fetal membranes on D18 of pregnancy,
but unlike human tissue at term, there was no increase
in uterine or placental Prok1. We confirmed localisation
of the ligand PROK1 and the receptor PROKR1 in mouse
fetal membranes by immunohistochemistry; thus,
endogenous PROK1–PROKR1 signalling could occur
in an autocrine and paracrine fashion. In addition, the
stronger PROK1 stain observed on D19 indicates that the
increase in Prok1 at the mRNA level is translated to
increased protein expression. The up-regulation of Prok1
mRNA and protein suggests an early role for PROK1
signalling in mouse parturition.
Parturition can be prematurely induced in mice by
intrauterine injection of a mimetic of infection such as
LPS (Pirianov et al. 2009). Intrauterine injection mimics
the major route of pathogen transmission in humans,
ascending from the vagina and cervix to reach
uteroplacental tissues where a local immune response
is induced leading to immune cell recruitment, synthesis
of prostaglandins, MMPs and ultimately PTD. Fetal
membranes are an attractive uteroplacental tissue to
target in the therapeutic treatment of PTD as infection
or inflammation in fetal membranes will result in
bi-directional release of pro-inflammatory mediators
into the amniotic fluid (and fetus, potentially causing
fetal inflammatory injury) or towards placenta and uterus
contributing to the initiation of parturition (Myatt & Sun
2010, Thiex et al. 2010).
In this study, we demonstrated that intrauterine
treatment with PROK1 or LPS induces significant
up-regulation of pro-inflammatory mediators in fetal
membranes (Il6, Il1b, Tnf, Cxcl2 and Cxcl5). We also
demonstrated that these pro-inflammatory genes are
significantly up-regulated in fetal membranes on D19 of
pregnancy (the day before parturition). Indeed, in vivo
PROK1-mediated induction of Ptgs2, Il6 and Il1b
cytokines by 6 h after treatment was comparable to
that seen endogenously on D19 of pregnancy. These pro-
inflammatory mediators are well documented to have
important roles in term labour and PTD; for example,
PTGS2 converts arachidonic acid into prostaglandins,
which stimulate uterine smooth muscle contractions
necessary for parturition (Challis et al. 1997), and
inhibition of Ptgs2 significantly reduces LPS-induced
PTD (Gross et al. 2000). Mice null for Il6 exhibit delayed
labour and a reduced sensitivity to LPS-induced PTD
(Robertson et al. 2010). Il1b mRNA levels increase in
mouse uteroplacental tissues at term (Sato et al. 2001),
and mice null for Il1b exhibit a reduced cytokineReproduction (2013) 146 581–591response to LPS (Reznikov et al. 1999). These data
suggest that one possible role for endogenous PROK1 in
fetal membranes could be to induce expression of other
pro-inflammatory mediators leading to the induction
of parturition at term. By contrast, our in vivo studies
suggest that the up-regulation of pro-inflammatory
mediators induced by exogenous PROK1 is insufficient
to induce PTD. This may be because PTD requires
greater production of pro-inflammatory mediators (for
example at levels induced by LPS) in order to overcome
any endogenous ‘brake’ on PTD.
This study identified that in response to LPS or PROK1
treatment, fetal membrane Cxcl2 expression was more
highly up-regulated than Cxcl5. Both are potent
neutrophil CXC chemokines known to increase in
response to LPS/infection in rodents and humans (Keelan
et al. 2004, Harju et al. 2005). By contrast, at term
parturition (D19 of pregnancy), the increase in Cxcl5
expression was greater than that in Cxcl2. CXCL5 is
expressed by epithelium in response to IL1B and TNF in
humans (Keelan et al. 2004). Therefore, the increase in
murine Cxcl5 in fetal membranes on D19 of pregnancy
seems likely to reflect increased expression by fetal
membrane epithelia; by contrast, Cxcl2 is produced by
macrophages. Intriguingly, neutrophil depletion does not
affect time to delivery (Timmons & Mahendroo 2006)
whereas macrophage depletion does prevent LPS-
induced PTD (Gonzalez et al. 2011). Taken together,
these data suggest that macrophage infiltration and
elevated Cxcl2 expression correlate with PTD, whereas
elevated Cxcl5 expression correlates with term parturi-
tion. Given that both CXCL2 and CXCL5 signal through
the GPCR CXCR2, further research is warranted to
investigate these chemokines as it may provide insight
into the difference between the regulation of term
parturition and PTD.
We also identified important differences between
mouse and human prokineticin involvement in term
labour and infection-induced PTD. Human myometrium
and placenta (but not fetal membranes) exhibit a
significant increase in PROK1 expression at labour
(Gorowiec et al. 2011). In addition, LPS increases
expression of PROK1 and PROKR1 in human uteropla-
cental tissues (Gorowiec et al. 2011). By contrast, here
we found that only mouse fetal membranes showed a
significant elevation of Prok1 preceding labour, and in
vivo administration of LPS did not regulate murine
expression of Prok1 or Prokr1 within 6 h. These data
suggest that PROK1 and PROKR1 in mouse fetal
membranes are not among the early complement of
LPS-induced cytokines. This finding corroborates with
our result that although PROK1 itself is pro-
inflammatory, intrauterine injection of PROK1 is not
sufficient to induce PTL. This result may be due to the
lack of significant up-regulation of the inflammatory
markers at the protein level as demonstrated by ELISA for
CXCL2, TNF and IL1B in amniotic fluid 6 h afterwww.reproduction-online.org
Prokineticin 1 and mouse fetal membranes 589treatment. It is possible that a later time point may have
yielded a different result as there is a trend for increased
protein expression in response to PROK1 and it was
found that LPS did not significantly up-regulate IL1B in
amniotic fluid by 6 h.
Although the interval to birth was shorter after PROK1,
this was not statistically significant. A post hoc power
calculation shows that we would need 21 mice in each of
the natural delivery groups and the PROK1 group to have
90% power to show a difference (at the 5% significance
level) in the interval to delivery in the two groups. This
assumes equal numbers in each groups and that the mean
and S.D. of the time to delivery remain the same in each
group. Hence, our study is underpowered to determine
whether the relatively subtle effect of PROK1 on short-
ening time to delivery by 28% is statistically significant.
The effect of LPS was profound, shortening the interval to
delivery by 74%. Our study had 89% power to detect a
shortening effect of PROK1 of time to delivery by 37%.
We can be confident that anyeffect of PROK1 on inducing
PTD (if it exists) is less than half as powerful as LPS in
shortening the interval to delivery (in the doses given). In
contrast to the possible type II error for a subtle effect of
PROK1 on inducing PTD, there was no difference in pup
survival between the PROK1 and the saline groups; thus,
even if there is a modest effect of PROK1 on PTD, it does
not compromise offspring survival.
At term, both humans and mice demonstrate elevated
maternal inflammatory responsiveness while maintaining
a relatively quiescent in utero environment (Orsi et al.
2007, Yuan et al. 2009). It has been hypothesised that this
allows rapid induction of labour by priming the maternal
inflammatory response to a trigger of parturition while
protecting the fetus from fetal inflammatory injury that
could be caused by premature exposure to inflammation.
We have shown that classic markers of parturition
increase significantly in fetal membranes on the day
prior to labour (D19) while Prok1 increases on D18;
therefore, the ability of PROK1 to induce expression of
these pro-inflammatory markers suggests that the
endogenous increase in Prok1 expression in fetal
membranes on D18 may lead to induction of pro-
inflammatory mediator expression and labour. Why we
were unable to induce this with exogenous treatment on
D17 remains unclear, although it is possible that a higher
dose of PROK1 would have been more effective.
It has been demonstrated in fetal sheep lung that
inflammation and immune cell recruitment in response
to LPS treatment promotes lung maturation (Kallapur
et al. 2005). This is an important factor in the survival and
morbidity of the neonate (Jobe & Ikegami 2001) and may
even be a trigger for parturition produced by the fetus
(Condon et al. 2004, Harju et al. 2005). Thus, the
endogenous increase in Prok1 and its relatively mild pro-
inflammatory properties (compared with LPS) may
promote fetal maturation and potentially the induction
of term labour. This hypothesis is consistent with ourwww.reproduction-online.orgfinding that PROK1 treatment, although pro-
inflammatory, did not reduce pup survival. We can
also speculate that as time to delivery was unaffected in
PROK1-treated dams, the endogenous pro-inflammatory
role of PROK1 is not to induce parturition through
induction of a strong inflammatory response but to
promote fetal maturation. This hypothesis may be
supported by our finding that Prok1 expression peaks
on D18, and not on D19 like the other pro-inflammatory
mediators analysed, suggesting that in the mouse,
transient endogenous expression occurs rather than a
prolonged amplification of pro-inflammatory mediator
expression driven by PROK1 as hypothesised to occur in
humans (Catalano et al. 2010, Gorowiec et al. 2011).
In conclusion, we have shown that PROK1 has a pro-
inflammatory effect on fetal membranes but intrauterine
injection is insufficient to induce PTD. However, we have
shown that fetal membranes exhibit dynamic regulation
of Prok1 prior to the up-regulation of other pro-
inflammatory mediators before parturition. This suggests
an alternate as yet unidentified role similar to that in fetal
maturation processes in term parturition in the mouse.
We have also demonstrated differences between human
and mouse prokineticin expression and regulation in
response to LPS in uteroplacental tissues, demonstrating
that caution should be applied when using mouse models
of PTD. Lastly, we have also contributed to the building
body of evidence that PTD is not simply the premature
induction of the same pro-inflammatory cascades seen
at term by showing the difference in regulation of
chemokines at term and in response to LPS, highlighting
potentially new targets for the treatment of PTD.Supplementary data
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